Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
|
|
SLO
|
ENG
|
Cookies and privacy
DKUM
EPF - Faculty of Business and Economics
FE - Faculty of Energy Technology
FERI - Faculty of Electrical Engineering and Computer Science
FF - Faculty of Arts
FGPA - Faculty of Civil Engineering, Transportation Engineering and Architecture
FKBV - Faculty of Agriculture and Life Sciences
FKKT - Faculty of Chemistry and Chemical Engineering
FL - Faculty of Logistic
FNM - Faculty of Natural Sciences and Mathematics
FOV - Faculty of Organizational Sciences in Kranj
FS - Faculty of Mechanical Engineering
FT - Faculty of Tourism
FVV - Faculty of Criminal Justice and Security
FZV - Faculty of Health Sciences
MF - Faculty of Medicine
PEF - Faculty of Education
PF - Faculty of Law
UKM - University of Maribor Library
UM - University of Maribor
UZUM - University of Maribor Press
COBISS
Faculty of Business and Economic, Maribor
Faculty of Agriculture and Life Sciences, Maribor
Faculty of Logistics, Celje, Krško
Faculty of Organizational Sciences, Kranj
Faculty of Criminal Justice and Security, Ljubljana
Faculty of Health Sciences
Library of Technical Faculties, Maribor
Faculty of Medicine, Maribor
Miklošič Library FPNM, Maribor
Faculty of Law, Maribor
University of Maribor Library
Bigger font
|
Smaller font
Introduction
Search
Browsing
Upload document
Statistics
Login
First page
>
Show document
Show document
Title:
Biosimilars and the patent law
Authors:
ID
Świerczyński, Marek
(Author)
ID
Więckowski, Zbigniew
(Author)
Files:
https://journals.um.si/index.php/medicine/article/view/404
Description: Prost dostop
Language:
English
Work type:
Unknown
Typology:
1.01 - Original Scientific Article
Organization:
PF - Faculty of Law
Abstract:
Biopharmaceuticals are one of the most important recent medical innovations which revolutionised many areas of medicine. Dynamic development of the market for biopharmaceuticals in recent years is related to the expiration of the IP exclusive rights on original innovative biological medicinal products. This has resulted in introduction to the market of biosimilars. One of the greatest challenges concerning the emergence of biosimilars is modifying the law to ensure balance between the market development of biosimilars and access of patients to biological therapy. The development of biopharmaceutical inventions works hand in hand with the patent system. It should be underlined that IP rights in the biopharmaceutical sector are crucial for promoting innovation due to the very long time of product development. It is exactly the area in which patents make sense to fill the gap between innovation and the risk of imitation. However, the existing patent system is too expensive and slow for biotechnology development. It should be further adapted to the needs of biopharmaceuticals.
Keywords:
biopharmaceuticals
,
biologic medicinal product
,
IP exclusive rights
,
innovation
,
intellectual property
Year of publishing:
2019
Number of pages:
str. 21-38
Numbering:
Vol. 12, iss. 2
PID:
20.500.12556/DKUM-78496
UDC:
347.78
ISSN on article:
2463-7955
COBISS.SI-ID:
43517443
DOI:
10.18690/mls.12.2.21-38.2019
NUK URN:
URN:SI:UM:DK:USZXJYAA
Publication date in DKUM:
15.01.2021
Views:
970
Downloads:
66
Metadata:
Categories:
Misc.
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Average score:
(0 votes)
Your score:
Voting is allowed only for
logged in
users.
Share:
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.
Comments
Leave comment
You must
log in
to leave a comment.
Comments (0)
0 - 0 / 0
There are no comments!
Back
